Purchase

Recombinant Mouse MerTK protein (rFc Tag) (HPLC verified)

Species

Mouse

Purity

>90 %, SDS-PAGE
>90%, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg2866


Product Information

Purity >90 %, SDS-PAGE
>90%, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Mouse MerTK protein Glu23-Phe498 (Accession# Q60805) with a rabbit IgG Fc tag at the C-terminus.
GeneID 17289
Accession Q60805
PredictedSize 78.2 kDa
SDS-PAGE 90-110 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

MerTK (Mer tyrosine kinase), also known as RP38, c-Eyk, c-mer, and Tyro12, was first cloned from a human B lymphoblastoid expression library (PMID:8086340) and is one of the TAM (Tyro-3, Axl, and MerTK) receptor tyrosine kinase (RTK) family (PMID:23833304). Although this RTK, like others, can promote tumor cell proliferation to some extent, MERTK primarily lends tumor cells crucial survival advantages while promoting invasion, migration and metastasis, drug resistance, and, in the innate immune system, suppressing anti-tumor immunity (PMID:32417270). The multiple MERTK species observed are likely due to posttranslational modifications (PMID: 23585477).

References:

1. Graham DK. et al. (1994). Cell Growth Differ. 5(6):647-57. 2. Cummings CT. et al. (2013). Clin Cancer Res. 1;19(19):5275-80. 3. Huelse JM. et al. (2020). Pharmacol Ther. 213:107577. 4. Schlegel J. et al. (2013). J Clin Invest. 123(5):2257-67.